Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017.
Kyaw Win SM, Saito R, Win NC, Lasham DJ, Kyaw Y, Lin N, Thein KN, Chon I, Odagiri T, Thein W, Kyaw LL, Tin OS, Saitoh A, Tamura T, Hirokawa C, Uchida Y, Saito T, Watanabe S, Odagiri T, Kamata K, Osada H, Dapat C, Watanabe H, Tin HH. Kyaw Win SM, et al. Among authors: watanabe s, watanabe h. PLoS One. 2020 Mar 4;15(3):e0229601. doi: 10.1371/journal.pone.0229601. eCollection 2020. PLoS One. 2020. PMID: 32130243 Free PMC article.
Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic.
Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, Kumazaki M, Usuku S, Tanaka N, Okubo I, Morita H, Nagata S, Watanabe S, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: watanabe s. Influenza Other Respir Viruses. 2021 Jul;15(4):488-494. doi: 10.1111/irv.12854. Epub 2021 Mar 14. Influenza Other Respir Viruses. 2021. PMID: 33715290 Free PMC article.
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: watanabe s. N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: watanabe s. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: watanabe s. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9. N Engl J Med. 2022. PMID: 35263535 Free PMC article. No abstract available.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: watanabe s. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. Nature. 2022. PMID: 35576972 Free PMC article.
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H. Hashimoto M, et al. Among authors: watanabe s. Vaccine. 2022 Jul 29;40(31):4231-4241. doi: 10.1016/j.vaccine.2022.05.081. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691872 Free PMC article.
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K, Tsuchimoto K, Iwanami S, Moriyama S, Kinoshita H, Yamada S, Kuroda Y, Yamamoto T, Kishida N, Watanabe S, Hasegawa H, Ebihara H, Suzuki T, Maeda K, Fukushi S, Takahashi Y, Iwami S, Watashi K. Ohashi H, et al. Among authors: watanabe s. Antiviral Res. 2022 Sep;205:105372. doi: 10.1016/j.antiviral.2022.105372. Epub 2022 Jul 4. Antiviral Res. 2022. PMID: 35798223 Free PMC article.
10,496 results
You have reached the last available page of results. Please see the User Guide for more information.